SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Certara, Inc. – ‘8-K’ for 6/14/21

On:  Monday, 6/14/21, at 12:25pm ET   ·   For:  6/14/21   ·   Accession #:  1104659-21-80617   ·   File #:  1-39799

Previous ‘8-K’:  ‘8-K’ on 5/20/21 for 5/18/21   ·   Next:  ‘8-K’ on 6/22/21 for 6/17/21   ·   Latest:  ‘8-K’ on / for 2/29/24   ·   5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/14/21  Certara, Inc.                     8-K:5       6/14/21   10:192K                                   Toppan Merrill/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     30K 
 6: R1          Cover                                               HTML     49K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 5: XML         XBRL Instance -- tm2119612d1_8k_htm                  XML     15K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.LAB  XBRL Labels -- cert-20210614_lab                     XML     96K 
 4: EX-101.PRE  XBRL Presentations -- cert-20210614_pre              XML     64K 
 2: EX-101.SCH  XBRL Schema -- cert-20210614                         XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    33K 
10: ZIP         XBRL Zipped Folder -- 0001104659-21-080617-xbrl      Zip     12K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0001827090  i false 0001827090 2021-06-14 2021-06-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of 

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  i June 14, 2021

 

 i Certara, Inc.

(Exact name of registrant as specified in its charter)

 

 i Delaware  i 001-39799  i 82-2180925
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
     
 i 100 Overlook Center    
 i Suite 101    
 i Princeton,  i New Jersey    i 08540
(Address of principal executive offices)   (Zip Code)

 

( i 609)  i 716-7900 

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 i ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 i ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 i ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
 i Common stock, par value $0.01 per share    i CERT    i The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company, as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  i x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  i ¨

 

 

 

 C: 

 

 

Item 5.02Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

On June 11, 2021, pursuant to the amended and restated bylaws of Certara, Inc. (the “Company), the Board of Directors of the Company (the “Board”) increased the number of Board members from eight (8) to nine (9), effective as of June 15, 2021, and designated the newly created vacancy as a Class III director.

 

On June 11, 2021, the Board elected the following individual to fill such vacancy, effective as of June 15, 2021:

 

Carol G. Gallagher, PharmD., age 56. Since October 2014, Dr. Gallagher served as a partner with New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Dr. Gallagher served as a venture partner with Frazier Healthcare, a venture capital firm, from October 2013 to September 2014. Dr. Gallagher served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead Sciences. From 2007 to 2008, Dr. Gallagher was the President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Prior to that time starting in 1989, she served in various roles at pharmaceutical companies Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Idec Pharmaceuticals, CancerVax and Anadys Pharmaceuticals. In addition to our Board, Dr. Gallagher serves as a director at the following public companies: Millendo Therapeutics, Inc., a biotechnology company, where she has served as a member of the board of directors since 2012; Turning Point Therapeutics, Inc., a biotechnology company, where she has served since August 2019, Frazier Life Sciences Acquisition Corp, a special purpose acquisition company, since October 2020 and Atara Biotherapeutics, Inc. a biotechnology company, where she served as a member of the board of directors since 2013. She previously served on the boards of directors at Anaptys Bio Inc. from 2011 until 2018 and Metacrine, Inc. from 2018 until April 2021.

 

The Board has appointed Dr. Gallagher to serve as a member of the Compensation Committee, and a member of the Nominating and Corporate Governance Committee.

 

Dr. Gallagher will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation policy described in “Executive Compensation−Director Compensation” of the Company's Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2021. The Company intends to enter into an indemnification agreement with Dr. Gallagher substantially similar to the indemnification agreements the Company has entered into with other members of the Board.

 

 C: 

 

 

 

SignatureS

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CERTARA, INC.
  (Registrant)
   
   
 
Date: June 14, 2021 By: /s/ Richard M. Traynor
    Richard M. Traynor
    Senior Vice President and General Counsel

 

 C: 

 

 

 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
6/15/213,  4,  4/A
Filed on / For Period end:6/14/214
6/11/214
4/8/21DEF 14A
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/19/21  Certara, Inc.                     424B4      11/18/21    1:2.3M                                   Toppan Merrill/FA
11/15/21  Certara, Inc.                     S-1                    4:2.8M                                   Toppan Merrill/FA
11/09/21  Certara, Inc.                     DRS11/15/21    1:2.4M                                   Toppan Merrill/FA
 9/09/21  Certara, Inc.                     424B4                  1:3.8M                                   Toppan Merrill/FA
 9/03/21  Certara, Inc.                     S-1                    4:4.3M                                   Toppan Merrill/FA
Top
Filing Submission 0001104659-21-080617   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 8:50:58.2pm ET